The headline EPS result beat the market’s bar, but revenue slightly missed. Nektar posted GAAP loss per share of $1.23 versus published consensus near $2.04, while revenue came in at $10.1 million versus roughly $10.5 million expected.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $10.1M *(Financial Highlights)* | $11.2M | Down 9% |
| R&D expense | $39.1M *(Financial Highlights)* | $29.9M | Up 31% |
| Operating costs and expenses | $52.5M *(Financial Highlights)* | $47.4M | Up 11% |
| Net loss | $(40.6)M *(Income Statement)* | $(41.6)M | Improved 2% |
| GAAP loss per share | $(1.23) *(Income Statement)* | $(2.95) | Improved 58% |
| Weighted-average shares | 33.1M *(Income Statement)* | 14.1M | Up 135% |
| Cash and investments | $1.02B *(Balance Sheet)* | $245.8M | Up sharply |
The EPS improvement overstates the underlying operating progress. Net loss improved only modestly, while the weighted-average share count more than doubled, making the per-share loss look dramatically better. At the same time, R&D spending rose $9.2 million as Phase 3 ZENITH activities and manufacturing ramped. *(Financial Highlights; Income Statement)*
The strategic picture strengthened through funding, not earnings power. Cash, short-term investments, and long-term investments totaled approximately $1.02 billion at quarter-end, with management projecting runway into the third quarter of 2028 and initial Phase 3 readouts in mid-2028. *(Balance Sheet; Management Commentary)* The balance sheet also shows capital in excess of par value rising by roughly $901 million, consistent with substantial equity financing; that explains the dilution behind the per-share result. *(Balance Sheet)*
Net read: a narrow earnings beat, tempered by weaker revenue quality and dilution. The filing supports continued execution toward Phase 3, but it does not show commercial momentum: royalty revenue declined, operating losses remained heavy, and development costs are accelerating. Against consensus, the EPS beat is enough for a “Beat” scorecard, but the favorable signal is narrower than the headline suggests.
Read the original 8-K on SEC EDGAR ↗